FDAnews Drug Daily Bulletin

Biopharmaceutical maker Repligen stands to receive $750,000 after settling a royalty dispute with one of its product developers, privately held drug maker ChiRhoClin. Waltham-based Repligen said the payment stems from "failed" obligations related to a product-licensing agreement with ChiRhoClin regarding SecreFlo, a diagnostic tool used to identify chronic pancreatitis and certain cancers. Approved by the U.S. Food and Drug Administration, SecreFlo, a synthetic form of porcine (pig-derived) secretin, is also used to aid gastrointestinal disorders.

Boston Business Journal (http://boston.bizjournals.com/boston/stories/2005/05/09/daily23.html)